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 The aim of present study was to formulate and evaluate Rabeprazole sodium and 
Domperidone pellets for the treatment of gastro esophageal reflux disease. Modified release 
drug delivery systems were capable of drug release when and where it requires. In the present 
study delayed release Rabeprazole sodium pellets were prepared by a drug layering, seal 
coating and enteric coating by using eudragit L100 55 as enteric coating material different 
weight gains were developed and evaluated for optimized formula and Sustained release 
Domperidone pellets were prepared by drug layering, sustained release coating with ethyl 
cellulose 7 cps as sustained release material. The formulated coated pellets were evaluated for 
angle repose, bulk density, tapped density, hausener ratio, Carr’s index, FTIR, DSC. Moisture 
content. In vitro release and acid-resistance studies were carried out in simulated gastric fluid 
and simulated intestinal fluid, respectively. The results indicated that Rabeprazole sodium 
pellets with  seal coat of  10 % (F13) formula and 30% of enteric coat with eudragit L 100 55 
(F30) formula showed good acid resistance and drug release. Domperidone pellets with 10 % 
(F9) and 12 % (F10) formulas of extended release coating with ethyl cellulose were showed 
required sustained action. The optimized formulations were evaluated for different release 
kinetics and found that Rabeprazole delayed release pellets were following First order and 
Korsemeyer-peppas equation Hence the release mechanism was by concentration dependent 
dissolution process. Domperidone pellets were following First order and Higuchi’s equation 
Hence the release mechanism was by concentration dependent diffusion process. F20 formula 
of rabeprazole pellets and F10 of formula domperidone pellets were showed required release 
characteristics were selected and filled in to the capsules.  
Please cite this article in press as Palepu. Swathi et al. Formulation and Evaluation of Rabeprazole Sodium and Domperidone 
Pellets. Indo American Journal of Pharmaceutical Research.2017:7(07). 
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INTRODUCTION 
Gastro esophageal reflux disease (GERD) is a common chronic, relapsing condition caused by the combination of excess 
reflux of gastric juice and impaired clearance of this refluxate from the esophagus. It is one of the most prevalent gastrointestinal 
disorders affecting all age groups and carries a risk of significant morbidity and possible mortality from resultant complications thus 
affecting the quality of life of the patient.[1,2] 
GERD is commonly due to transient or permanent changes in the barrier between the esophagus and the stomach, which can 
be due to incompetence of the lower esophageal sphincter (LES), transient LES relaxation, impaired expulsion of gastric refluxate 
from the esophagus, or association with a hiatal hernia. Reflux of gastric contents can cause esophageal mucosal abnormalities, such 
as ulcers and peptic strictures, as well as reflux-induced asthma and acid laryngitis. Left untreated esophageal adenocarcinoma can 
develop in approximately 0.2 - 2.0% of patients with Barrett’s esophagus, a complication of GERD.[2-5] 
Goals of GERD management include symptom control, promoting mucosal healing, preventing complications and symptom 
relapse, and improving health-related quality of life. Today, proton pump inhibitors (PPIs) have largely supplanted the H2RAs with 
superior efficacy in suppression of gastric acid secretion.9 A significant percentage of patients with GERD also have delayed gastric 
emptying. Prokinetic drugs correct this defect without altering gastric acidity. These agents improve lower esophageal sphincter 
competence, esophageal clearance and gastric emptying.10 Therefore in GERD patients failing to Rabeprazole alone, combination of 
Rabeprazole and prokinetic agent may be more useful. [8-12] 
A major fact that Rabeprazole sodium is drug of focus for recent years as the patent protection for the Rabeprazole molecule 
expired in Canada at the end of 2007, As stability of Rabeprazole sodium is poor. In particular it is rapidly decomposed and colored 
under moist conditions or in an acidic to neutral aqueous solution. A sustained release action of Domperidone is needed. Design of 
multi particulate pellets dosage form has more advantageous over conventional tablet dosage forms.  
Hence the present work aims to formulate delayed release pellets of Rabeprazole sodium and sustained release pellets of 
Domperiodone by using different polymers and optimization of the formulation. 
 
Pelletization 
Pellets :  
Pellets
 
can be defined as small, free flowing, spherical or semi-spherical solid units, typically from about 0.5 mm to 1.5 mm, 
and intended usually for oral administration, manufactured by the agglomerates of fine powders or granules of  bulk drugs and 
excipients using appropriate processing equipment. Pellets can be prepared by many methods, the compaction and drug-layering being 
the most widely used today.[13-15] 
 
Pellets have to meet the following requirements: 
 They should be near spherical and have a smooth surface; both considered optimum characteristics for subsequent film coating. The 
particle size range should be as narrow as possible.  
 The optimum size of pellets for pharmaceutical use is considered to be between 600 and 1000mm. 
 The pellets should contain as much as possible of the active ingredient to keep the size of the final dosage form within reasonable 
limits. They should be near spherical and have a smooth surface; both considered optimum characteristics for subsequent film 
coating.[16-18]. 
 
The most common advantages of pelletization are: 
 Improved appearance of the product and the core is pharmaceutically elegant. 
 Pelletization offers flexibility in dosage form design and development. 
 Pellets are less susceptible to dose dumping. 
 It reduces localized concentration of Irritative drugs. 
 It improves safety and efficacy of a drug. 
 Pellets offer reduced variation in gastric emptying rate and transit time. 
 Pellets disperse freely in G.I.T. and invariably maximize drug absorption and also reduce peak plasma fluctuation. 
 Pellets ensure improved flow properties in formulation development [19,20] 
 
MATERIALS AND METHODS 
Materials: 
Rabeprazole sodium, Domperidone, L-HPC LH21, Titanium dioxide, Povidone K 30 and Medium chain triglycerides  are the 
gifted samples from Ortin laboratories, Sodium carbonate, Sodium hydroxide, Sodium lauryl Sulphate, are obtained from AVA 
Chemicals Pvt, Ltd. cellulose Ether K100M, HPMC E5, Propylene glycol, Eudragit L 100 55, Triethyl citrate, Hydroxyl propyl 
cellulose E5, Ethyl cellulose 7 cpsp and talc are procured from Zeel Pharmaceuticals. 
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Methods:  
Preparation Rabeprazole Pellets 
Preparation of Core Pellets 
Rabeprazole sodium core pellets were prepared by drug solution layering onto nonpareil seeds in bottom spray fluid-bed 
processor. Aqueous solution of hypromellose E 5 was prepared by dissolving it in purified water with stirring. Magnesium oxide  was 
added to solution of step 1 with stirring and the solution stirred continuously until it dissolved completely. Rabeprazole sodium was 
dissolved in solution of step 2 with stirring to get a clear solution. Add binder to the above solution. Nonpareil seeds were charged in a 
bottom spray fluid-bed processor and drug solution was continuously sprayed over them under an optimized set of process variables to 
obtain drug pellets.  After the completion of drug layering, the pellets were dried in the fluid-bed processor until loss on drying (LOD) 
of less than 2% w/w was attained. The dried drug pellets were sifted to collect 16 to 20 mesh fraction. Undersize and oversize drug 
pellets were discarded. 
 
Table 1: Formulation of core pellets. 
 
 
 
Preparation of Seal-Coated Pellets: 
The primary objective of applying seal coat on rabeprazole sodium pellets was to separate the drug layer from the outermost 
enteric layer which is acidic in nature. Direct contact of acidic enteric layer with the drug would otherwise result in destabilization of 
drug and generation of impurities. Hypromellose Or HPMCE5 was dispersed and dissolved with stirring in purified water. Titanium 
dioxide, propylene glycol 6000, was dispersed in the hypromellose solution with stirring to produce the seal coating dispersion.LOD 
value is critical to stability of drug since higher level of moisture content may lead to destabilization of drug. The dried seal-coated 
drug pellets were sifted to collect 16 to 20 mesh fractions. 
 
Table 2:Formulation of Barrier Coating. 
 
 
 
 
 
 
 
 
 
 
Preparation of Delayed-Release Pellets 
Preparation of organic polymer solution dissolve the eudragit polymer in iso propyl alcohol followed by incorporation of 
plastcizer . This is then followed by drying of the pellets at 40°C for 1 hour to LOD ≤2% w/w and subsequent screening of the dried 
pellets to collect 14 to 18 mesh fractions. 
 
Table 3:Formulation of enteric coated pellet: 
 
 
Formu 
lation 
code 
Non 
pareil 
Seeds(g) 
Rabeprazo
le sodium 
(g) 
Sodium 
carbonate 
(g) 
Sodium 
hydroxide 
(g) 
Low Substituted 
Hydroxy propyl 
cellulose LH21(g) 
cellulose 
Ether 
K100M (g) 
Sodium lauryl 
Sulphate (g) 
HPM
C E5 
(g) 
Purifie
d 
Water 
F1 50 20 40  20  2 4 q.s 
F2 50 20  40 20  2 4 q.s 
F3 50 20 40  10  2 4 q.s 
F4 50 20 40  30  2 4 q.s 
F5 50 20 40   10 2 4 q.s 
F6 50 20 40   20 2 4 q.s 
F7 50 20 40   30 2 4 q.s 
F8 50 20 40   40 2 4 q.s 
Formulation code Core pellets Barrier coating Enteric coating (30%) 
F9 (2%) 135 2.7 41.31 
F10 (4%) 135 5.4 42.12 
F11 (6%) 135 8.1 42.93 
F12 (8%) 135 10.8 43.74 
F13 (10%) 135 13.5 44.55 
F14 (12%) 135 16.2 45.36 
F15 (14%) 135 18.9 46.17 
Ingredients Core pellets(F2) Barrier coating(10%) Enteric coating 
F16 (10%) 135 13.5 14.85 
F17 (15%) 135 13.5 22.2 
F18 (20%) 135 13.5 29.7 
F19 (25%) 135 13.5 37.1 
F20 (30%) 135 13.5 44.5 
F21 (35%) 135 13.5 51.8 
F22 (40%) 135 13.5 59.4 
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PREPARATION OF DOMPERIDONE PELLETS 
 
Table 4: Formulation  of  Domperidone Core Pellet. 
 
Formula
tion code 
Micro crystalline 
cellulose spheres (gm) 
Domperido
ne (gm) 
Hydroxyl propyl 
cellulose E5 (gm) 
Isopropyl 
alcohol (gm) 
Water Dissolution Angle of 
repose 
F1 100 30 5 q.s q.s 96 96.4 
F2 100 30 10 q.s q.s 94 96.5 
F3 100 30 15 q.s q.s 85 97.8 
F4 100 30 20 q.s q.s 70 92 
 
Pellets were prepared in Bottom spray FBC the process parameters were same as preparation of  Core Pellets of rabeprazole 
by following the table 4. 
 
Coating solution preparation 
 Hydroxy propyl cellulose was dissolved in solvent prepared by mixing 30:70 water ,methnol and separately dissolve the 
domperidone drug in the same solvent mixture then add both the solutions by vigorous stirring.  Dissolve ethyl cellulose and povidone 
separately in solvent mixture of water and iso propyl alcohol then add medium chain try glyceride to the above solution. Sprayed on 
the core pellets by fluidized bed coater.  
 
Table 5: Formulation of Extended Release Pellets. 
 
 
 
 
 
 
 
 
 
 
Evaluation studies 
FTIR measurements 
 
 
 
Figure 1: Rabeprazole optimized sample and Rabeprazole sodium pure drug. 
 
 
 
Figure 2:Domperidone optimized sample and Domperidonene Pure Drug. 
 
 
 
 
 
 
Formulation code Core Drug layering Extended release coating 
F5(2%) 100 45 2.9 
F6(4%) 100 45 5.8 
F7(6%) 100 45 8.7 
F8(8%) 100 45 11.6 
F9(10%) 100 45 14.5 
F10(12%) 100 45 17.4 
F11(14%) 100 45 20.3 
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FT-IR spectra of Rabeprazole alone and its combination with excipients are shown in the Figure1. FTIR spectra of the pure 
rabeprazole and the drug excipients mixture showed characteristic bands at 2801.12 cm
-1
, 1743.21 cm
–1
, 1423.22cm
–1
, 1206.12 cm
–1
 
and 923.22 cm
–1
 due to functional groups, indicating the chemical stability of rabeprazole in the chosen polymeric mixture. This also 
indicates that rabeprazole is not involved in any chemical reactions with the excipients used. 
FT-IR spectra of domperidone alone and its combination with excipients are shown in the Figur 2. FTIR spectra of the pure 
domperidone and the drug excipients mixture showed characteristic bands at 2962.03 cm
-1
, 1692.34 cm
–1
, 1428.12 cm
–1
, 1115.67 cm
–1
 
and 724.34 cm
–1
 due to functional groups, indicating the chemical stability of domperidone in the chosen polymeric mixture. This also 
indicates that domperidone is not involved in any chemical reactions with the excipients used. 
 
CHARACTERIZATION OF RABEPRAZOLE SODIUM PELLETS 
 
Table 6: Pre formulation studies of core pellets. 
 
 
 
 
 
 
 
 
 
 
 
Table 7:Dissolution profile of core pellets. 
 
 
 
 
 
 
 
 
 
 
Based on the analysis performed and differences occurred in values of angle of repose, percentage moisture content 
,dissolution F1 formulation was fixed for the core pellet preparation as shown in table 6 and 7. 
 
Table 8:Characterization of Barrier Coating. 
 
Formulation code Assay 
F9 (2%) 67.5 
F10 (4%) 75.2 
F11 (6%) 83.6 
F12 (8%) 92.3 
F13 (10%) 96.20 
F14 (12%) 97 
F15 (14%) 97 
 
Seal coating was done on to the optimized core pellet formulae (F1) and fixed enteric coat formula used and different 
percentage weight gains were developed and evaluated based on the assay values F13 formulation was fixed for the seal coat. 
 
Table 9:Characterization of enteric coated pellet. 
 
 
 
 
 
 
 
 
 
Formulation code Angle of Repose Bulk Density Tapped Density Carr’s Index Hausner’s Ratio 
F1 23.5± 0.08 0.78± 0.01 0.82±0.01 16.8 1.05 
F2 42.1± 0.14 0.78± 0.01 0.82±0.01 16.6 1.04 
F3 22.6±1.36 0.78± 0.01 0.82±0.01 16.9 1.06 
F4 22.8±0.15 0.78± 0.01 0.82±0.01 16.8 1.05 
F5 34.2±0.63 0.78± 0.01 0.82±0.01 16.6 1.04 
F6 36.3±0.04 0.78± 0.01 0.82±0.01 16.9 1.06 
F7 32.4±0.06 0.78± 0.01 0.82±0.01 16.6 1.04 
F8 33.8±0.06 0.78± 0.01 0.82±0.01 16.8 1.04 
Formulations 10 min 20 min 30min 45min 
F1 84 92 96 99 
F2 87 90 98 100 
F3 95 98 100 101 
F4 76 85 90 94 
F5 90 94 99 101 
F6 90 96 98 101 
F7 87 95 98 101 
F8 82 90 96 100 
Formulation Code CDR in 0.1N HCL CDR in Tris buffer pH at 45 min Assay 
F16 (10%) 30% 96.5 97.1 
F17 (15%) 25% 97.5 97 
F18 (20%) 15% 98.6 96.7 
F19 (25%) 8% 92.4 97 
F20 (30%) 4% 98.5 97 
F21 (35%) 2% 95.2 97 
F22 (40%) 2% 83.7 96.4 
                                                   
www.iajpr.com 
P
ag
e2
4
0
 
Vol 7, Issue 07, 2017.                                                     Palepu. Swathi et al.                                                     ISSN NO: 2231-6876 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The enteric coat was optimized by performing the acid resistance test the formulation which released very less amount in the 
acidic media was selected and assay and dissolution in buffer media were performed.Optimization of enteric coat was done by using 
F1 core formula and F13 seal coat formula and based on the analysis concluded that F20 and F21 formulations were suitable for the 
preparation. 
 
EVALUATION OF DOMPERIDONE PELLETS 
 
Table 10:Preformulation Studies Domperidone Core Pellets. 
 
Formulation code Angle of Repose Bulk Density  Tapped Density Carr’s Index Hausner’s Ratio 
F1 22.3  0.82  0.86  16.8  1.05  
F2 23.4  0.83  0.85  16.8  1.04  
F3 21.3  0.83  0.87  16.3  1.04  
F4 22.2  0.82  0.85  16.7  1.05  
 
Extended release coating was done on to the F3 formula of core pellets then developed different weight gains of extended 
release  pellets as shown in table 10.                     
 
Table 11: Dissolution profile of domperidone: 
 
 
 
 
 
 
 
 
 
 
 
 
Based on the evaluation parameters F9,F10 formulations were found to be best formulations as shown in the table 11. 
 
Kinetic Studies: 
Rabeprazole delayed release pellets were following First order and Korsemeyer-peppas equation Hence the relese mechanism 
was by concentration dependent dissolution process. 
Domperidone pellets were following First order and Higuchi’s equation Hence the release mechanism was by concentration dependent 
diffusion process. 
 
CONCLUSIONS 
Preformulation studies were performed before formulation development the drug and excipients werefound to be compatable. 
Rabeprazole sodium and Domperidone pellets were prepared by using different excipients for rabeprazole sodium pellets F1 
formulation (containg sodium carbonate as alkalizing material and L-HPC as polymer) for core pellets,F13 formulation (with 10 % 0f 
seal coat) for seal coat and F20 formulation (with 30 % of eudragit coating) for enteric coating were optimized respectively based on 
diferent preformulation and evaluation parameters and for domperidone pellets F3 formulation(with hydroxyl propyl polymer at a 
concentration of 15 5 W/V) for core ,F9,F10 formulation (with 10 % and 12 % sustained release coating with ethyl cellulose 7 cps) for 
sustained release coating were optimized respectively. 
Optimized formuloins were studied for different release kinetics Based on the regression values analyzed for different order 
of reactions Rabeprazole delayed release pellets were following First order and Korsemeyer-peppas equation Hence the release 
mechanism was by concentration dependent dissolution process. 
Based on the regression values analyzed for different order of reactions Domperidone pellets were following First order and 
Higuchi’s equation Hence the release mechanism was by concentration dependent diffusion process. 
F20 formulation (with 10 % seal coat and 30% delayed release coat) of rabeprazole pellets and F10 formulation (with 12 % sustained 
release coat with ethylcellulose 7 cps) of domperidone pellets were selected and filled in to the capsules.  
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Time F5 F6 F7 F8 F9 F10 F11 
Acid stage 
0.5hr 60 54 48 43 35 23.4 15.9 
1 hr 75.2 68.4 65.4 56.6 49.4 44.5 31,2 
Buffer stage 
2nd hr 80.2 78.3 76.7 67.5 58.4 49.2 58.6 
3rd hr 89.6 84.3 79.6 73.4 88.9 75.6 65.4 
4th hr 94.3 89.7 86.5 76.8 91.1 85.4 74.9 
5th hr 97.3 96.4 94.5 74.3 93.2 87.5 75.2 
6th hr 98 97.8 97 85.4 94.6 92.4 78.3 
7th hr  98  98  97  92  97.5  93.4  82.3  
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